Axitinib__VEGFR kinase inhibitor Azeliragon
Product Name
Axitinib
Description
VEGFR kinase inhibitor
Purity
>98% (HPLC)
CAS No.
319460-85-0
Molecular Formula
C22H18N4OS
Molecular Weight
386.5
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble to 25 mM in DMSO
Source
Synthetic
Appearance
White to tan powder
SMILES
CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
InChI
InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
InChIKey
RITAVMQDGBJQJZ-FMIVXFBMSA-N
Safety Phrases
Classification:
Acute toxicity, Oral (Category 4), H302
Acute aquatic toxicity (Category 1), H400
Chronic aquatic toxicity (Category 1), H410
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H302 Harmful if swallowed.
H410 Very toxic to aquatic life with long lasting effects
Precautionary statements:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.
P330 Rinse mouth.
P391 Collect spillage.
P501 Dispose of contents/ container to an approved waste disposal plant.
Cite This Product
Axitinib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-494)
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19116032
Alternative Names
AG-013736, N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide, N-Methyl-3(1E)-2-(2-pyridinyl)ethenyl-1H-indazol-6-ylthio-benzamide
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cardiovascular System, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
6450551
Scientific Background
Axitinib is a potent and selective tyrosine kinase inhibitor that blocks VEGF receptors 1, 2 and 3. It has also been shown to inhibit PDGFR-β and c-Kit.
References
1. Hu-Lowe D.D., et al. (2008) Clin. Cancer Res: J. Am. Ass. Cancer Res. 14(22): 7272–7283.
VEGFR kinase inhibitor
Acute toxicity, Oral (Category 4), H302
Acute aquatic toxicity (Category 1), H400
Chronic aquatic toxicity (Category 1), H410
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Hazard statements:
H302 Harmful if swallowed.
H410 Very toxic to aquatic life with long lasting effects
Precautionary statements:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.
P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.
P330 Rinse mouth.
P391 Collect spillage.
P501 Dispose of contents/ container to an approved waste disposal plant.